Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy offers hope for melanoma patients who failed standard treatment

NCT ID NCT02965716

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial studies a combination of two immunotherapy drugs—talimogene laherparepvec (T-VEC) and pembrolizumab—in 43 adults with advanced melanoma that has worsened despite prior anti-PD1/L1 therapy. T-VEC is a modified virus that infects and kills cancer cells while also stimulating the immune system, and pembrolizumab helps immune cells attack the tumor. The goal is to see if this combination can shrink tumors and control the disease in patients with limited options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MELANOMA RECURRENT MELANOMA STAGE III CUTANEOUS MELANOMA AJCC V7 STAGE IIIA CUTANEOUS MELANOMA AJCC V7 STAGE IIIB CUTANEOUS MELANOMA AJCC V7 STAGE IIIC CUTANEOUS MELANOMA AJCC V7 STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7 UNRESECTABLE MELANOMA

Contacts and locations

Locations

  • Allegiance Health

    Jackson, Michigan, 49201, United States

  • CTCA at Western Regional Medical Center

    Goodyear, Arizona, 85338, United States

  • Henry Ford Cancer Institute-Downriver

    Brownstown, Michigan, 48183, United States

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

  • Henry Ford Macomb Hospital-Clinton Township

    Clinton Township, Michigan, 48038, United States

  • Henry Ford West Bloomfield Hospital

    West Bloomfield, Michigan, 48322, United States

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utah, 84112, United States

  • Indiana University/Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana, 46202, United States

  • Kansas City Veterans Affairs Medical Center

    Kansas City, Missouri, 64128, United States

  • Keck Medical Center of USC Pasadena

    Pasadena, California, 91105, United States

  • Los Angeles General Medical Center

    Los Angeles, California, 90033, United States

  • Loyola University Medical Center

    Maywood, Illinois, 60153, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California, 90095, United States

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • University of Cincinnati Cancer Center-UC Medical Center

    Cincinnati, Ohio, 45219, United States

  • University of Cincinnati Cancer Center-West Chester

    West Chester, Ohio, 45069, United States

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas, 66205, United States

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama, 36688, United States

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.